AmplifyBio

News

AmplifyBio to Drive Quality Excellence
with Veeva Vault Quality Suite

      Fast-growing CRO will bring together quality processes, content, and training to streamline quality management and accelerate preclinical validation for cutting-edge medicines PLEASANTON, CA — May 3, 2022 – Veeva Systems (NYSE: VEEV) today announced that AmplifyBio is building a foundation for advanced quality, study execution, and reporting with Veeva Vault Quality Suite. Using a modern quality system with built-in industry best practices, the company will

Read More »

AmplifyBio to Attend Society for Toxicology 2022

  AmplifyBio will be exhibiting at the Society of Toxicology Meeting in San Diego, California: May 27th – May 31st. Like many people, the team at AmplifyBio is looking forward to getting out and meeting with customers and colleagues in person again.  AmplifyBio is a leading preclinical CRO focused on toxicology, safety and pharmacology testing to advance therapeutics for the betterment of human health. Spun out of

Read More »

Battelle, Partners to Form New Company: AmplifyBio

$200 million start-up will focus on development of next generation therapies COLUMBUS, Ohio (May 3, 2021) — Battelle announced today that it is launching a new company that will focus on the research and development of next generation therapies such as cell and gene therapies (CGT). AmplifyBio will operate on its own 30-acre dedicated footprint within Battelle’s West Jefferson, Ohio campus. The new company has the

Read More »